Day: March 7, 2023

Patriot Reports Fourth Quarter 2022 Net Income of $1.8 million, $0.45 per share; Full Year Net Income of $6.2 million, $1.56 per share

Written by Customer Service on March 7, 2023. Posted in Earnings Releases And Operating Results.

Pre-tax Income and Net Interest Margin buoyed by exceptional loan and deposit growth STAMFORD, Conn., March 07, 2023 (GLOBE NEWSWIRE) — Patriot National Bancorp, Inc. (“Patriot,” “Bancorp” or the “Company”) (NASDAQ: PNBK), the parent company of Patriot Bank, N.A. (the “Bank”), today announced net income of $1.8 million, or $0.45 basic and diluted earnings per share for the quarter ended December 31, 2022. These results compare to net income of $2.3 million, or $0.59 basic and diluted earnings per share for the third quarter of 2022 and net income of $1.9 million, or $0.48 basic and diluted earnings per share reported in the fourth quarter of 2021. Net income for the full year ended December 31, 2022 was $6.2 million, or $1.56 basic and $1.55 diluted earnings per share, compared to a net income of $5.1 million, or $1.29 basic and...

Interim Dividend Declarations

Written by Customer Service on March 7, 2023. Posted in Dividend Reports And Estimates.

Dividend Declaration Seneca Growth Capital VCT Plc 7 March 2023 Seneca Growth Capital VCT Plc Interim Dividend Declarations The Directors of Seneca Growth Capital VCT Plc (the “Company”) are pleased to declare the following dividends for both the B Share Class and the Ordinary Share Class for the year to 31 December 2023:1.5 pence per B Share interim dividend; and 2.0 pence per Ordinary Share interim capital dividend.The ex-dividend date for both dividends is 4 May 2023. The record date for both dividends is 5 May 2023. The payment date for both dividends is 19 May 2023. On 26 August 2022 the Company launched an offer for subscription for B Shares to raise, in aggregate, up to £10 million with an over-allotment facility of up to a further £10 million (before issue costs) (the “Offer”). Full details of the Offer are contained...

Lithium North Project Acquired By DIOS, James Bay, Quebec

Written by Customer Service on March 7, 2023. Posted in Mergers And Acquisitions.

DIOS LITHIUM NORTH PROJECT LOCATION DIOS JAMES BAY Lower Eastmain Greenstone Belt PropertiesMONTREAL, March 07, 2023 (GLOBE NEWSWIRE) — Dios Exploration (TSX-V: DOS) reports having acquired large Lithium North project some 12-20 km north of its Lithium33 property totalling 136 wholly-owned claims for 7142 hectares in James Bay prolific lithium region of Quebec, Canada. Lithium North covers two pegmatite prospective sections: 1) NE-SW striking 13 km-long section and 2) NW-SE 6 km long one, both hosting porphyritic/pegmatitic granodiorite with pegmatite pockets and 5-50% dykes, wrapped around a magnetic biotite granite. Lithium North lies within a greenstone belt sub-province and outside the limits of former Tyrell Sea (so its sediment values are more reliable as they were not swept all over the sea). Dios’ project is well located...

Neuronetics Reports Record Fourth Quarter and Record Full Year 2022 Financial and Operating Results

Written by Customer Service on March 7, 2023. Posted in Earnings Releases And Operating Results.

MALVERN, Pa., March 07, 2023 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced its financial and operating results for the fourth quarter and full year of 2022. Fourth Quarter 2022 HighlightsFourth quarter 2022 revenue of $18.2 million, representing a 21% increase as compared to the fourth quarter 2021 Achieved record U.S. treatment session revenue of $12.5 million in the fourth quarter 2022 Increased NeuroStar System revenue 64% over the fourth quarter of 2021Full Year 2022 HighlightsFull year 2022 revenue of $65.2 million, representing an 18% increase as compared to full year 2021 Full year 2022 U.S. treatment...

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

Written by Customer Service on March 7, 2023. Posted in Public Companies.

Shareholders approve 26th consecutive dividend increase to CHF 3.20 (+3.2%) per share for 2022; representing a 4.0% yield1 and approximately 61% payout of free cash flowShareholders confirm Joerg Reinhardt as Chair of the Board of Directors as well as all other members who stood for re-election; John D. Young newly elected to the Board of DirectorsShareholders approve all other proposals of the Board of Directors, including the amendment of the Articles of Incorporation, the 2022 Compensation Report in an advisory vote, as well as the future Board and Executive Committee compensation in separate binding votesBasel, March 7, 2023 — Novartis shareholders today agreed to the Board of Directors’ recommendations for all proposed resolutions at the Group’s Annual General Meeting (AGM). A total of 1507 shareholders were present at the...

Fortress Biotech to Participate in Two March 2023 Investor Conferences

Written by Customer Service on March 7, 2023. Posted in Public Companies.

MIAMI, March 07, 2023 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in two investor conferences in March 2023. Details of the events are as follows:35th Annual ROTH Conference: The company will participate in a fireside chat on Monday, March 13, 2023, at 9:00 a.m. PT and will attend one-on-one meetings during the conference. A webcast of the fireside chat will be available on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the meeting. Oppenheimer...

Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference

Written by Customer Service on March 7, 2023. Posted in Public Companies.

MALVERN, Pa., March 07, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a fireside chat at the 35th Annual Roth Conference scheduled for March 12-14, 2023 at the Ritz Carlton, Laguna Niguel in Dana Point, California. Details regarding Ocugen’s fireside chat are as follows: Event: 35th Annual Roth Conference Date: Monday, March 13, 2023 Time: 9 a.m. PDT Location: Healthcare Salon – Salon 5 – The Ritz Carlton, Dana Point, California Dr. Musunuri will highlight Ocugen’s progress across its integrated pipeline and provide an overview of anticipated...

Baker Hughes and HIF Global to Collaborate on Direct Air Capture Technology

Written by Customer Service on March 7, 2023. Posted in Public Companies.

Agreement enables pilot testing to more quickly scale-up deployment of Direct Air Capture solutionsHOUSTON, March 07, 2023 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR), an energy technology company, and HIF Global, the world’s leading eFuels company, announced Tuesday their agreement to cooperate on the development of technology to capture carbon dioxide directly from the atmosphere (“CO2 Direct Air Capture” or “DAC”). More specifically, HIF Global and Baker Hughes intend to test Baker Hughes’ Mosaic DAC technology pilot units to accelerate DAC deployment at commercial scale. Cesar Norton, HIF Global CEO, said, “Groundbreaking technologies like Mosaic that enable efficient, low-cost CO2 capture from our atmosphere represent the future of CO2 recycling. Cooperation with our partner Baker Hughes on this important DAC initiative...

Clene Nanomedicine to Participate in Roth’s 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series

Written by Customer Service on March 7, 2023. Posted in Public Companies.

SALT LAKE CITY, March 07, 2023 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that it will participate in Roth’s 35th Annual Healthcare Conference set for March 12th-14th and in Renmark Financial Communications Inc.’s Virtual Non-Deal Roadshow Series on March 7th and 22nd. EVENT DETAILS: Roth 35th Annual Healthcare Conference, March 12-14 Presentation/Fireside Chat Time: March 13 starting at 3:30 p.m. E.D.TWebcast link: https://wsw.com/webcast/roth46/clnn/1826765 The webcast of this presentation will be posted to the Investors section of the Company’s website located at www.invest.clene.com. Renmark Virtual...

Absci to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Written by Customer Service on March 7, 2023. Posted in Public Companies.

VANCOUVER, Wash. and NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Absci management is scheduled to participate in a fireside chat on Tuesday March 21st at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com. About Absci Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success...

Day: March 7, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice